CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
Clinical trials for CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION explained in plain language.
Never miss a new study
Get alerted when new CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION trials appear
Sign up with your email to follow new studies for CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New heart failure drug shows promise in Real-World chinese study
Disease control CompletedThis study collected data from 2,400 Chinese adults with chronic heart failure to see how well the drug vericiguat works compared to standard care. The main goal was to see if vericiguat could prevent death from heart problems or hospital stays due to heart failure. Researchers a…
Matched conditions: CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
Sponsor: Bayer • Aim: Disease control
Last updated May 26, 2026 12:04 UTC
-
Heart failure drug shows promise in major trial
Disease control CompletedThis study tested a drug called vericiguat in over 6,000 adults with chronic heart failure and reduced pumping ability. The goal was to see if it could lower the chance of dying from heart problems or being hospitalized for heart failure. Participants took the drug or a placebo a…
Matched conditions: CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 12:01 UTC
-
Can a higher starting dose of heart failure drug speed up treatment?
Symptom relief CompletedThis study tested whether starting the heart failure drug vericiguat at a 5 mg dose (instead of the usual 2.5 mg) is safe and tolerable for people with chronic heart failure with reduced ejection fraction. 106 participants took the 5 mg dose for 2 weeks. The goal was to see if sk…
Matched conditions: CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
Phase: PHASE2 • Sponsor: Bayer • Aim: Symptom relief
Last updated May 20, 2026 11:54 UTC
-
Heart drug vericiguat under the microscope: Real-World results from 500 patients
Knowledge-focused CompletedThis study looked at data from 500 people in Germany who were prescribed vericiguat for chronic heart failure with reduced ejection fraction (a weak heart). Researchers wanted to see how well the drug works in everyday medical care, not just in a controlled trial. They measured d…
Matched conditions: CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
Sponsor: Bayer • Aim: Knowledge-focused
Last updated May 26, 2026 12:12 UTC
-
Heart failure drug vericiguat under the microscope in japan
Knowledge-focused CompletedThis study looked at medical records from nearly 5,000 Japanese adults with chronic heart failure who started taking vericiguat as part of their regular care. Researchers tracked hospital stays, deaths, and how well patients followed their treatment for up to one year. The goal w…
Matched conditions: CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
Sponsor: Bayer • Aim: Knowledge-focused
Last updated May 22, 2026 14:03 UTC